Gregory Renza
Stock Analyst at Truist Securities
(4.13)
# 517
Out of 5,116 analysts
242
Total ratings
43.27%
Success rate
16.86%
Average return
Main Sectors:
Stocks Rated by Gregory Renza
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AGIO Agios Pharmaceuticals | Maintains: Buy | $32 → $38 | $28.02 | +35.62% | 8 | Dec 24, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Buy | $14 → $18 | $11.58 | +55.44% | 5 | Dec 11, 2025 | |
| REGN Regeneron Pharmaceuticals | Assumes: Buy | $812 → $798 | $784.97 | +1.66% | 1 | Nov 24, 2025 | |
| CATX Perspective Therapeutics | Assumes: Buy | $8 → $12 | $2.88 | +316.67% | 7 | Nov 24, 2025 | |
| NRIX Nurix Therapeutics | Assumes: Buy | $23 → $30 | $19.30 | +55.44% | 12 | Nov 24, 2025 | |
| GILD Gilead Sciences | Assumes: Buy | $145 → $140 | $124.70 | +12.27% | 1 | Nov 24, 2025 | |
| AMGN Amgen | Assumes: Hold | $298 → $318 | $332.93 | -4.48% | 18 | Nov 24, 2025 | |
| XNCR Xencor | Initiates: Buy | $29 | $15.22 | +90.54% | 10 | Nov 24, 2025 | |
| VRDN Viridian Therapeutics | Initiates: Buy | $41 | $31.88 | +28.61% | 12 | Nov 24, 2025 | |
| NUVB Nuvation Bio | Initiates: Buy | $11 | $9.40 | +17.02% | 7 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $140 | $104.10 | +34.49% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $5.79 | +55.44% | 2 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $59 | $35.18 | +67.71% | 13 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $62 | $39.84 | +55.62% | 4 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $10 | $6.82 | +46.63% | 4 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $312.39 | +28.05% | 3 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $27.68 | +84.25% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $140 | $142.31 | -1.62% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $45 → $50 | $46.24 | +8.13% | 11 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $35 | $220.80 | -84.15% | 3 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $27.62 | -5.87% | 16 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $3.51 | +127.92% | 12 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $5 | $2.29 | +118.34% | 11 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $182 → $172 | $170.48 | +0.89% | 14 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $113 → $38 | $85.74 | -56.26% | 14 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $12.53 | -4.23% | 6 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $8.06 | +73.70% | 10 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $18 | $26.51 | -32.10% | 11 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $48 | $1.76 | +2,627.27% | 4 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $110 → $20 | $8.16 | +145.10% | 7 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $16 | $0.74 | +2,054.01% | 1 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $2,160 → $180 | $18.37 | +879.86% | 4 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $100 → $80 | $0.98 | +8,061.60% | 5 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $105 → $30 | $0.30 | +9,843.65% | 3 | Jun 2, 2020 |
Agios Pharmaceuticals
Dec 24, 2025
Maintains: Buy
Price Target: $32 → $38
Current: $28.02
Upside: +35.62%
Fulcrum Therapeutics
Dec 11, 2025
Maintains: Buy
Price Target: $14 → $18
Current: $11.58
Upside: +55.44%
Regeneron Pharmaceuticals
Nov 24, 2025
Assumes: Buy
Price Target: $812 → $798
Current: $784.97
Upside: +1.66%
Perspective Therapeutics
Nov 24, 2025
Assumes: Buy
Price Target: $8 → $12
Current: $2.88
Upside: +316.67%
Nurix Therapeutics
Nov 24, 2025
Assumes: Buy
Price Target: $23 → $30
Current: $19.30
Upside: +55.44%
Gilead Sciences
Nov 24, 2025
Assumes: Buy
Price Target: $145 → $140
Current: $124.70
Upside: +12.27%
Amgen
Nov 24, 2025
Assumes: Hold
Price Target: $298 → $318
Current: $332.93
Upside: -4.48%
Xencor
Nov 24, 2025
Initiates: Buy
Price Target: $29
Current: $15.22
Upside: +90.54%
Viridian Therapeutics
Nov 24, 2025
Initiates: Buy
Price Target: $41
Current: $31.88
Upside: +28.61%
Nuvation Bio
Nov 24, 2025
Initiates: Buy
Price Target: $11
Current: $9.40
Upside: +17.02%
Nov 24, 2025
Initiates: Buy
Price Target: $140
Current: $104.10
Upside: +34.49%
Nov 24, 2025
Initiates: Buy
Price Target: $9
Current: $5.79
Upside: +55.44%
Nov 24, 2025
Initiates: Buy
Price Target: $59
Current: $35.18
Upside: +67.71%
Nov 24, 2025
Initiates: Buy
Price Target: $62
Current: $39.84
Upside: +55.62%
Nov 24, 2025
Initiates: Hold
Price Target: $10
Current: $6.82
Upside: +46.63%
Nov 24, 2025
Initiates: Buy
Price Target: $400
Current: $312.39
Upside: +28.05%
Nov 24, 2025
Initiates: Buy
Price Target: $51
Current: $27.68
Upside: +84.25%
Nov 24, 2025
Initiates: Buy
Price Target: $140
Current: $142.31
Upside: -1.62%
Jul 8, 2025
Downgrades: Sector Perform
Price Target: $45 → $50
Current: $46.24
Upside: +8.13%
May 23, 2025
Maintains: Outperform
Price Target: $31 → $35
Current: $220.80
Upside: -84.15%
May 19, 2025
Reiterates: Outperform
Price Target: $26
Current: $27.62
Upside: -5.87%
May 15, 2025
Reiterates: Outperform
Price Target: $8
Current: $3.51
Upside: +127.92%
May 14, 2025
Reiterates: Sector Perform
Price Target: $5
Current: $2.29
Upside: +118.34%
May 7, 2025
Maintains: Outperform
Price Target: $182 → $172
Current: $170.48
Upside: +0.89%
Apr 16, 2025
Maintains: Sector Perform
Price Target: $113 → $38
Current: $85.74
Upside: -56.26%
Mar 26, 2025
Reiterates: Outperform
Price Target: $12
Current: $12.53
Upside: -4.23%
Mar 21, 2025
Maintains: Outperform
Price Target: $16 → $14
Current: $8.06
Upside: +73.70%
Jan 14, 2025
Reiterates: Sector Perform
Price Target: $18
Current: $26.51
Upside: -32.10%
Jan 9, 2025
Maintains: Outperform
Price Target: $68 → $48
Current: $1.76
Upside: +2,627.27%
Nov 5, 2024
Downgrades: Sector Perform
Price Target: $110 → $20
Current: $8.16
Upside: +145.10%
Aug 14, 2024
Reiterates: Outperform
Price Target: $16
Current: $0.74
Upside: +2,054.01%
Jun 27, 2023
Downgrades: Sector Perform
Price Target: $2,160 → $180
Current: $18.37
Upside: +879.86%
Mar 16, 2022
Maintains: Sector Perform
Price Target: $100 → $80
Current: $0.98
Upside: +8,061.60%
Jun 2, 2020
Downgrades: Sector Perform
Price Target: $105 → $30
Current: $0.30
Upside: +9,843.65%